215 related articles for article (PubMed ID: 36255605)
21. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab.
Veccia A; Sforza V; Vattemi E; Inno A; Kinspergher S; Dipasquale M; Gori S; Morabito A; Baldi I; Caffo O
Immunotherapy; 2021 Sep; 13(13):1093-1103. PubMed ID: 34190578
[TBL] [Abstract][Full Text] [Related]
22. Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
Ortega-Franco A; Hodgson C; Raja H; Carter M; Lindsay C; Hughes S; Cove-Smith L; Taylor P; Summers Y; Blackhall F; Califano R
Target Oncol; 2022 Jul; 17(4):453-465. PubMed ID: 35781861
[TBL] [Abstract][Full Text] [Related]
23. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
25. Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer.
Chen Y; Wen S; Xia J; Du X; Wu Y; Pan B; Zhu W; Shen B
Front Immunol; 2021; 12():672271. PubMed ID: 34054853
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung.
Tashima Y; Kuwata T; Yoneda K; Hirai A; Mori M; Kanayama M; Imanishi N; Kuroda K; Ichiki Y; Tanaka F
Sci Rep; 2020 Jan; 10(1):1243. PubMed ID: 31988315
[TBL] [Abstract][Full Text] [Related]
27. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
28. Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy.
Julian C; Machado RJM; Girish S; Chanu P; Heinzmann D; Harbron C; Gershon A; Pfeiffer SM; Zou W; Quarmby V; Zhang Q; Chen Y
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1578. PubMed ID: 35075804
[TBL] [Abstract][Full Text] [Related]
29. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ
Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053
[TBL] [Abstract][Full Text] [Related]
30. The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis.
Huang Y; Shen A
Medicine (Baltimore); 2020 Aug; 99(34):e21718. PubMed ID: 32846790
[TBL] [Abstract][Full Text] [Related]
31. [Predictive Value of LIPI and iSEND Immune Scoring System
in Immunotherapy of Advanced Non-small Cell Lung Cancer].
Luo Y; Wang X; Wang Y; Zhang G
Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):803-810. PubMed ID: 36419394
[TBL] [Abstract][Full Text] [Related]
32. dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50.
Holtzman L; Moskovitz M; Urban D; Nechushtan H; Keren S; Reinhorn D; Wollner M; Daher S; Rottenberg Y; Rovitzky Y; Shochat T; Bar J; Dudnik E
Clin Lung Cancer; 2022 Mar; 23(2):122-134. PubMed ID: 35034862
[TBL] [Abstract][Full Text] [Related]
33. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer.
Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M
Thorac Cancer; 2020 Jun; 11(6):1578-1586. PubMed ID: 32286017
[TBL] [Abstract][Full Text] [Related]
34. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
[TBL] [Abstract][Full Text] [Related]
35. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
Banna GL; Signorelli D; Metro G; Galetta D; De Toma A; Cantale O; Banini M; Friedlaender A; Pizzutillo P; Garassino MC; Addeo A
Transl Lung Cancer Res; 2020 Aug; 9(4):1533-1542. PubMed ID: 32953525
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.
Tanaka S; Uchino J; Yokoi T; Kijima T; Goto Y; Suga Y; Katayama Y; Nakamura R; Morimoto K; Nakao A; Hibino M; Tani N; Takeda T; Yamaguchi H; Tachibana Y; Takumi C; Hiraoka N; Takeshita M; Onoi K; Chihara Y; Taniguchi R; Yamada T; Matsui Y; Hiranuma O; Morimoto Y; Iwasaku M; Tokuda S; Kaneko Y; Yamada T; Takayama K
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204513
[TBL] [Abstract][Full Text] [Related]
38. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
39. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
